Hyderabad-based pharmaceutical major Dr Reddy’s Laboratories Limited (DRL) has launched Nexret, a drug for treatment of acne, in India.
Nexret is a next generation anti-acne formulation made from a proprietary non-porous microsphere technology. "This unique technology minimises irritation associated with drugs like Tretinoin and provides controlled delivery of drug to the skin," the company stated in a press release.
The anti-acne market in India is estimated to be about Rs 130 crore and is growing at the rate of about 14 per cent per annum.
Topical Tretinoin is considered as one of the most efficacious drug to treat acne, a commonly diagnosed condition by dermatologists. However, its use is restricted because of irritation, erythema, burning and dryness.
According to DRL, Nexret contains Tretinoin entrapped in microspheres enabling more amount of drug loading and also reducing unwanted adverse effects. This microsphere technology has been developed internally and patent application has been filed in seven countries.
Nexret is available in gel formulation and in pack size of 15 gm.
The anti-acne market in India is estimated to be about Rs 130 crore and is growing at the rate of about 14 per cent per annum.
Topical Tretinoin is considered as one of the most efficacious drug to treat acne, a commonly diagnosed condition by dermatologists. However, its use is restricted because of irritation, erythema, burning and dryness.
According to DRL, Nexret contains Tretinoin entrapped in microspheres enabling more amount of drug loading and also reducing unwanted adverse effects. This microsphere technology has been developed internally and patent application has been filed in seven countries.
Nexret is available in gel formulation and in pack size of 15 gm.
No comments:
Post a Comment